269 related articles for article (PubMed ID: 7523732)
21. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.
Chan TY; Partin AW; Walsh PC; Epstein JI
Urology; 2000 Nov; 56(5):823-7. PubMed ID: 11068310
[TBL] [Abstract][Full Text] [Related]
23. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening.
Hoedemaeker RF; Rietbergen JB; Kranse R; Schröder FH; van der Kwast TH
J Urol; 2000 Aug; 164(2):411-5. PubMed ID: 10893598
[TBL] [Abstract][Full Text] [Related]
24. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
[TBL] [Abstract][Full Text] [Related]
25. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles.
Johnson CW; Anastasiadis AG; McKiernan JM; Salomon L; Eaton S; Goluboff ET; Olsson CA; Benson MC
Urol Oncol; 2004; 22(2):107-11. PubMed ID: 15082006
[TBL] [Abstract][Full Text] [Related]
26. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
27. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Amling CL; Blute ML; Lerner SE; Bergstralh EJ; Bostwick DG; Zincke H
Mayo Clin Proc; 1998 May; 73(5):401-6. PubMed ID: 9581578
[TBL] [Abstract][Full Text] [Related]
28. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract][Full Text] [Related]
29. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
30. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.
Ohori M; Wheeler TM; Dunn JK; Stamey TA; Scardino PT
J Urol; 1994 Nov; 152(5 Pt 2):1714-20. PubMed ID: 7523718
[TBL] [Abstract][Full Text] [Related]
31. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.
Freedland SJ; Aronson WJ; Presti JC; Amling CL; Terris MK; Trock B; Kane CJ
Cancer; 2004 Apr; 100(8):1633-8. PubMed ID: 15073850
[TBL] [Abstract][Full Text] [Related]
32. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.
Trapasso JG; deKernion JB; Smith RB; Dorey F
J Urol; 1994 Nov; 152(5 Pt 2):1821-5. PubMed ID: 7523728
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens.
Algarra R; Barba J; Merino I; Tienza A; Tolosa E; Robles JE; Zudaire J
Actas Urol Esp; 2015 Apr; 39(3):144-53. PubMed ID: 24996780
[TBL] [Abstract][Full Text] [Related]
34. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification].
Koh H; Maru N; Muramoto M; Wheeler TM; Scardino PT; Ohori M
Nihon Hinyokika Gakkai Zasshi; 2002 Jul; 93(5):595-601. PubMed ID: 12174634
[TBL] [Abstract][Full Text] [Related]
35. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
[TBL] [Abstract][Full Text] [Related]
36. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
37. Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml. Or less.
D'Amico AV; Chen MH; Malkowicz SB; Whittington R; Renshaw AA; Tomaszewski JE; Samofalov Y; Wein A; Richie JP
J Urol; 2002 May; 167(5):2025-30; discussion 2030-1. PubMed ID: 11956431
[TBL] [Abstract][Full Text] [Related]
38. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy.
van den Ouden D; Hop WC; Schröder FH
J Urol; 1998 Oct; 160(4):1392-7. PubMed ID: 9751362
[TBL] [Abstract][Full Text] [Related]
39. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
40. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
Noguchi M; Stamey TA; Neal JE; Yemoto CE
J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]